This is an exciting time with great potential for discovering therapies to improve functional capacity and decrease the high prevalence of frailty and disability in older people. The FDA will need to consider how best to incorporate the geriatric perspective into its mission. Cooperation between aging researchers, pharmaceutical companies, and regulators will be required to establish guidelines for outcome measures for the coming generation of clinical trials in frail older persons. Ultimately, all stakeholders have the same goals: reducing the burden of chronic disease and disability in older persons while avoiding harm.
|Original language||English (US)|
|Number of pages||5|
|Journal||Journals of Gerontology - Series A Biological Sciences and Medical Sciences|
|Publication status||Published - Feb 2008|
ASJC Scopus subject areas